Clinical trial NCT04593823: Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study
Official title: A Multicenter, Randomized, Open Label, Controlled Study Evaluating the Effectiveness and Safety of Furoscix On-Body Infusor vs Continued Medical Therapy for Worsening Heart Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Heart Failure
Lead sponsor: scPharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2020-10-20
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, open label, controlled study evaluating the effectiveness, and safety of the Furoscix Infusor vs continued medical therapy in patients with chronic heart failure and fluid overload requiring augmentation in diuretic therapy outside of acute care setting.

The study drug, Furoscix (furosemide injection 8 mg/ml), is a furosemide solution buffered to a neutral pH containing 80 mg/10 mL for subcutaneous administration over 5 hours via the Furoscix Infusor.

The study objectives are:

1. To provide pilot data on the effectiveness and safety to inform a pivotal trial.
2. To inform population enrichment strategies
3. To refine pivotal trial endpoints and analytical methods
4. To identify operational challenges of study design
5. To assess patient adherence, competence, and experience
6. To familiarize staff and patients with device application and use

Detailed description: The purpose of this study is to evaluate the effectiveness and safety of the Furoscix Infusor vs continued medical therapy in patients with chronic heart failure and fluid overload requiring augmentation in diuretic therapy outside of acute care setting. 51 patients will be randomly assigned (2:1) to receive Furoscix vs continued medical therapy.

The Treatment Phase comprises a pre-programmed bi-phasic 5-hour drug administration of Furoscix (80 mg/10 mL) via the On-body Infusor. Subjects and/or their caregivers will be trained on device preparation, placement and removal in accordance with product instructions of use (IFU). Subjects should be transitioned back to their oral maintenance diuretic regimen when clinically indicated at the discretion of the investigator.

Over the initial 7 days, all subjects will receive daily clinic or phone follow-up by the study staff. Decision of treatment with Furoscix in the intervention arm as well as changes in oral diuretic dosing in the control arm will be determined by the treating physician in coordination with the study nurse. Safety labs will be done on Days 1, 3, 7 and 30.

After Subjects have been transitioned to their oral maintenance diuretic regimen, additional doses of Furoscix (for Furoscix group) or IV diuretics (for Treat as Usual group) can be prescribed during the 30-day study period as needed based on the presence of congestion symptoms (e.g. dyspnea, edema, and/or excess weight gain) as determined by the investigator.

The Follow-Up Phase will include a visit to the clinic on Day 30 +/- 5 days where effectiveness and safety assessments will be performed including limited physical exam (including NYHA Class), Composite Congestion Score (CCS), 5-point Current Dyspnea Score, 7-point Dyspnea Score, vital signs, laboratory analyses, KCCQ-12, Visual Analog Score (VAS), 6MWT and adverse events.

Eligibility criteria: Inclusion Criteria:

Subjects are eligible for inclusion only if all the following criteria are met:

1. Age 18 years or older.
2. Diagnosis of symptomatic chronic heart failure (NYHA Class II-IV) with background loop diuretic therapy for at least 4 weeks.
3. Need for augmented diuresis outside of the acute care setting as determined by the investigator.
4. On background therapy including daily total furosemide equivalent dose (40-160 mg) of loop diuretic or equivalent.
5. The subject must have signs of volume expansion, defined as two or more of the following six signs:

   1. jugular venous distention
   2. edema (≥ 1+)
   3. ascites
   4. pulmonary congestion on chest x-ray
   5. pulmonary rales
   6. NT-proBNP ≥1000 pg/ml (1400 for patients in atrial fibrillation) or, for patients not on Entresto, BNP ≥200 (400 for patients in atrial fibrillation)
6. Increase over the preceding 30 days in at least one of the following symptoms characteristic of worsening heart failure:

   1. dyspnea
   2. fatigue
   3. exercise intolerance
7. Adequate environment for at home administration of Furoscix by patient or caregiver.

Exclusion Criteria:

A Subject is not eligible for inclusion if any of the following criteria apply:

1. Suspected high risk clinical instability with outpatient treatment.
2. Presence of a complicating condition, other than heart failure likely to require hospitalization in next 30 days.
3. Pregnant women or women of childbearing age who are not willing to use an adequate form of contraception.
4. Known allergy to the active and inactive ingredients of the study medication or device adhesive.
5. On experimental medication or currently participating in another interventional research study.
6. eGFR \< 20
7. Serum potassium at baseline \> 5.4 or \< 3.6
8. Concomitant infection
9. Heart rate \> 110
10. Received IV furosemide or bumetanide within last 24 hours

Primary outcomes:
measure: Win Ratio of Composite Endpoint
timeFrame: Day 7, Day 30
measure: Number of Cardiovascular Deaths
timeFrame: Baseline, 30 Days
measure: Number of Heart Failure Hospitalizations
timeFrame: 30 Days
measure: Number of Urgent ED/Clinic Visits for Worsening Heart Failure
timeFrame: 30 Days
measure: NT-proBNP Change From Baseline
timeFrame: 30 Days
Secondary outcomes:
measure: Number of Heart Failure Event Free Survival Days
timeFrame: 30 Days
measure: Number of Subjects Deceased or HF Event Occurred
timeFrame: 30 Days
measure: Visual Analog Scale (VAS)
timeFrame: Baseline, 7 Days, 30 Days
measure: Composite Congestion Score (CCS)
timeFrame: Baseline, Day 7, Day 30
measure: 5-Point Current Dyspnea Score
timeFrame: Baseline, Day 7, Day 30
measure: 7-Point Dyspnea Score
timeFrame: Baseline, Day 3, Day 7, Day 30
measure: KCCQ-12 Summary Score
timeFrame: Baseline, 7 Days, 30 Days
measure: Six-Minute Walk Test (6MWT)
timeFrame: Baseline, 7 Days, 30 Days
measure: Percent Lung Fluid
timeFrame: Baseline, Day 7, Day 30
measure: Body Weight
timeFrame: Baseline, Day 3, Day 7, Day 30
measure: Renal Function
timeFrame: Baseline, Day 3, Day 7, Day 30
Other outcomes:
Locations:
city: Fairhope
country: United States
facility: Heart Group of Eastern Shore
state: Alabama
city: Huntsville
country: United States
facility: The Heart Center Research, LLC
state: Alabama
city: Hartford
country: United States
facility: Hartford Hospital
state: Connecticut
city: Aventura
country: United States
facility: Aventura Clinical Research, LLC
state: Florida
city: Gainesville
country: United States
facility: University of Florida
state: Florida
city: Hialeah
country: United States
facility: Elite Cardiac Research
state: Florida
city: Jacksonville
country: United States
facility: First Coast Cardiovascular Institute
state: Florida
city: Pensacola
country: United States
facility: Cardiology Consultants
state: Florida
city: Tampa
country: United States
facility: James A. Haley Veerans Hospital
state: Florida
city: Augusta
country: United States
facility: University Hospital - Augusta
state: Georgia
city: Downers Grove
country: United States
facility: Advocate Health and Hospitals
state: Illinois
city: Peoria
country: United States
facility: UnityPoint Health - Methodist Hospital
state: Illinois
city: Ypsilanti
country: United States
facility: Michigan Heart
state: Michigan
city: Saint Louis
country: United States
facility: St. Louis Heart and Vascular
state: Missouri
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai
state: New York
city: Greensboro
country: United States
facility: Cone Health Medical Group
state: North Carolina
city: Lancaster
country: United States
facility: Lancaster General Hospital
state: Pennsylvania
city: Madison
country: United States
facility: University of Wisconsin
state: Wisconsin
Study officials:
affiliation: Principal Investigator
name: Marvin A Konstam, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Principal Investigator
name: James E Udelson, MD
role: PRINCIPAL_INVESTIGATOR
References: